Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) is excited to announce its collaboration with Idea Evolver (IE), a leading technology platform specializing in Rx-to-OTC switches and digital pharmaceutical launch solutions. The partnership aims to create an application using IE's innovative Rx-to-OTC platform, CodeScripts, to facilitate the transition of Petros' erectile dysfunction drug, STENDRA® (avanafil), from prescription to over-the-counter (OTC).

Fady Boctor, President and Chief Commercial Officer of Petros, stressed the importance of this partnership in addressing the technological aspects crucial for the successful Rx-to-OTC switch of STENDRA. Boctor highlighted the significance of ensuring safe access to the OTC product for appropriate patients, contingent upon FDA approval. He also mentioned the potential integration of AI/machine learning components, developed in response to FDA feedback, to enhance the self-selection process.

Boctor expressed optimism about the collaboration, stating that Idea Evolver's unique position as the only technology provider with documented experience in advancing a drug through an Actual Use Trial for potential OTC approval is invaluable. Petros looks forward to further refining the STENDRA process through continued development of this tool, collaboration with additional partners, and ongoing engagement with the FDA.

Idea Evolver's track record includes collaborations with major healthcare organizations and participation in a groundbreaking technology-enabled prescription to OTC switch clinical study for rosuvastatin (Crestor). This study, also known as an Actual Use Trial, was published in the Journal of the American College of Cardiology in September 2021. Petros intends to leverage Idea Evolver's expertise in branding, consumer research, behavior analysis, and human factors/usability engineering to design the application. The partnership will also focus on incorporating artificial intelligence components to further enhance the tool's capabilities.

A Blockbuster Drug, as defined by Investopedia, is a pharmaceutical therapy generating over $1 billion in sales.

 

Source: accesswire.com

Report Abuse